Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Elizabeth Robins Gerstner, M.D.

Co-Author

This page shows the publications co-authored by Elizabeth Gerstner and Ugonma Chukwueke.
Connection Strength

0.277
  1. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat Commun. 2021 10 12; 12(1):5954.
    View in: PubMed
    Score: 0.062
  2. Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 Aug; 26(8):1309.
    View in: PubMed
    Score: 0.057
  3. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 08; 26(8):1280-1284.
    View in: PubMed
    Score: 0.056
  4. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020 04; 52(4):371-377.
    View in: PubMed
    Score: 0.056
  5. Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. NPJ Precis Oncol. 2017; 1(1):33.
    View in: PubMed
    Score: 0.047
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.